Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pliant Therapeutics (PLRX) PT Lowered to $45 at Oppenheimer
August 8, 2024 8:00 AM EDTOppenheimer analyst Jeff Jones lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $48.00) while maintaining a Outperform rating.... More
Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 7c
August 8, 2024 4:08 AM EDTPliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85).
For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.
... More